A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Seagen Inc.
Seagen Inc.
University of Nebraska
National Institutes of Health Clinical Center (CC)
Eisai Inc.
Acrotech Biopharma Inc.
Chipscreen Biosciences, Ltd.
Lymphoma Study Association
M.D. Anderson Cancer Center